Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vistin Pharma Capital/Financing Update 2018

May 25, 2018

3782_rns_2018-05-25_59a51850-caf7-4a8c-b3e0-d131d4c97ac5.html

Capital/Financing Update

Open in viewer

Opens in your device viewer

Vistin Pharma ASA : Last day of the subscription period in the subsequent repair issue

Vistin Pharma ASA : Last day of the subscription period in the subsequent repair issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR

INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY

OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE

UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE

SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF

THE ANNOUNCEMENT

Oslo, 25 May 2018: Reference is made to the stock exchange announcements dated

9 May 2018 and 14 May 2018 regarding the subsequent repair issue of up to

4,464,286 new shares (the "Offer Shares") in Vistin Pharma ASA ("Vistin Pharma"

or the "Company") at a subscription price of NOK 11.20 per share (the

"Subsequent Repair Issue").

The subscription period for the Subsequent Repair Issue will expire today, 25

May 2018, at 16:30 CEST. Correctly completed subscription forms must be received

by the subscription office, or, in the case of online subscriptions, be

registered, within this deadline. Subscription rights that are not used to

subscribe for Offer Shares within this deadline will have no value and lapse

without compensation to the holder.

For more information, please refer to the prospectus of the Company dated 9 May

2018. The Prospectus including the subscription form is available at the

following websites: http://www.vistin.com/ and www.dnb.no/emisjoner.

DNB Markets, a part of DNB Bank ASA, is acting as Manager for the Subsequent

Repair Issue.

This information is subject of the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Gunnar Manum

CFO

+47 951 79 190